In a study that measured SARS-CoV-2–specific antibodies, CD4+, and CD8+ T cells in participants with a range of COVID-19 disease severities, severe or fatal disease was shown to be associated with minimal or lacking SARS-CoV-2–specific CD4+ and CD8+ T cell responses (3). This evidence concerns the gene CD8A and COVID-19.